scholarly journals Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

2017 ◽  
Vol 41 (2) ◽  
pp. 755-768 ◽  
Author(s):  
Wei Zhang ◽  
Wenjie Xia ◽  
Zhengye Lv ◽  
Chao Ni ◽  
Yin Xin ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Tumor Development ◽  
Prognostic Information ◽  
Source Characteristics ◽  
Circulating Free Dna ◽  
Free Dna ◽  
And Personalized Medicine

Precision medicine and personalized medicine are based on the development of biomarkers, and liquid biopsy has been reported to be able to detect biomarkers that carry information on tumor development and progression. Compared with traditional ‘solid biopsy’, which cannot always be performed to determine tumor dynamics, liquid biopsy has notable advantages in that it is a noninvasive modality that can provide diagnostic and prognostic information prior to treatment, during treatment and during progression. In this review, we describe the source, characteristics, technology for detection and current situation of circulating tumor cells, circulating free DNA and exosomes used for diagnosis, recurrence monitoring, prognosis assessment and medication planning.

scholarly journals Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer

2022 ◽  
Vol 2022 ◽  
pp. 1-9
Author(s):  
Pengjie Yu ◽  
Shengmao Zhu ◽  
Yushuang Luo ◽  
Ganggang Li ◽  
Yongqiang Pu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Neoadjuvant Therapy ◽  
Advanced Gastric Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Circulating Free Dna ◽  
Free Dna ◽  
N Stage

Objective. To explore the application value of circulating tumor cells (CTCs) and circulating free DNA (cfDNA) from peripheral blood in the prognosis of advanced gastric cancer (AGC). Here, we measured CTCs and cfDNA quantity for predicting the outcome of patients. Patients and Methods. Forty-five patients with advanced gastric cancer who underwent neoadjuvant chemotherapy and surgical treatment were enrolled in this study. All patients received neoadjuvant chemotherapy with paclitaxel + S-1 + oxaliplatin (PSOX) regimen, and CTCs and cfDNA of the peripheral blood were detected before and after neoadjuvant therapy. Relationships between the number/type of CTC or cfDNA and the efficacy of neoadjuvant chemotherapy were analyzed. Results. Among 45 patients, 43 (95.6%) were positive, and the positive rate of mesenchymal CTC was increased with the increase in the T stage. The proportion of mesenchymal CTC was positively correlated with the N stage ( P < 0.05 ), and the larger N stage will have the higher proportion of mesenchymal CTC. Patients with a small number of mesenchymal CTC before neoadjuvant chemotherapy were more likely to achieve partial response (PR) with neoadjuvant therapy. Patients with positive CA-199 were more likely to achieve PR with neoadjuvant therapy ( P < 0.05 ). Patients in the PR group were more likely to have decreased/unchanged cfDNA concentration after neoadjuvant therapy ( P = 0.119 ). After neoadjuvant therapy (before surgery), the cfDNA concentration was higher and the efficacy of neoadjuvant therapy (SD or PD) was lower ( P = 0.045 ). Conclusions. Peripheral blood CTC, especially interstitial CTC and cfDNA, has a certain value in predicting the efficacy and prognosis of neoadjuvant chemotherapy in advanced gastric cancer.

Circulating Tumor Cells and Personalized Medicine

2021 ◽  
pp. 489-508
Author(s):  
Jin Sun Lee ◽  
Mark Jesus M. Magbanua ◽  
Marc R. Jabon ◽  
John W. Park
Keyword(s):  
Personalized Medicine ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
And Personalized Medicine

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

2017 ◽  
Vol 24 (3) ◽  
pp. 560-568 ◽  
Author(s):  
Giovanna Rossi ◽  
Zhaomei Mu ◽  
Alfred W. Rademaker ◽  
Laura K. Austin ◽  
Kimberly S. Strickland ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Advanced Breast ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

Cells ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 522 ◽  
Author(s):  
Patricia Mondelo-Macía ◽  
Carmela Rodríguez-López ◽  
Laura Valiña ◽  
Santiago Aguín ◽  
Luis León-Mateos ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Copy Number ◽  
Patients With Cancer ◽  
Circulating Free Dna ◽  
Free Dna ◽  
Met Amplification ◽  
Potential Biomarker

MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alterations in cancer patients. We analyzed MET amplification in circulating free DNA (cfDNA) from 174 patients with cancer and 49 healthy controls and demonstrated the accuracy of the analysis to detect its alteration in patients. Importantly, a significant correlation between cfDNA concentration and MET copy number (CN) in cancer patients (r = 0.57, p <10−10) was determined. Furthermore, we evaluated two approaches to detect the presence of MET on circulating tumor cells (CTCs), using the CellSearch® and Parsortix systems and monitored patients under anti-EGFR treatment (n = 30) combining both cfDNA and CTCs analyses. This follow-up provides evidence for the potential of MET CN assessment when patients develop resistance to anti-EGFR therapy and a significant association between the presence of CTCs MET+ and the Overall Survival (OS) in head and neck cancer patients (P = 0.05; HR = 6.66). In conclusion, we develop specific and noninvasive assays to monitor MET status in cfDNA/CTCs and demonstrate the utility of plasma MET CN determination as a biomarker for monitoring the appearance of resistance to anti-EGFR therapy.

Circulating Tumor Cells and Personalized Medicine

2017 ◽  
pp. 77-102
Author(s):  
Jin Sun Lee ◽  
Mark Jesus M. Magbanua ◽  
Marc R. Jabon ◽  
John W. Park
Keyword(s):  
Personalized Medicine ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
And Personalized Medicine

scholarly journals Analysis of colorectal cancer‐related mutations by liquid biopsy: Utility of circulating cell‐free DNA and circulating tumor cells

2019 ◽  
Vol 110 (11) ◽  
pp. 3497-3509 ◽  
Author(s):  
Kohki Takeda ◽  
Takeshi Yamada ◽  
Goro Takahashi ◽  
Takuma Iwai ◽  
Koji Ueda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Cell Free Dna ◽  
Free Dna ◽  
Circulating Cell Free Dna

scholarly journals Circulating tumor cells (CTC) and Cell-free DNA (cfDNA): Liquid biopsy for cancer diagnostics

2020 ◽  
Vol 9 (0) ◽  
pp. 59-63
Author(s):  
Ayaka Nakamura ◽  
Minako Abe ◽  
Yukie Saeki ◽  
Fumika Kono ◽  
Yasuha Ono ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Cancer Diagnostics ◽  
Cell Free Dna ◽  
Free Dna

Circulating free DNA and circulating tumor cells as new serum biomarkers in advanced ovarian cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 5566-5566
Author(s):  
Jeronimo Martinez Garcia ◽  
Asuncion Soto ◽  
Pilar Sanchez-Henarejos ◽  
Ana Puertes Boix ◽  
Edith Rodriguez ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Malignant Tumors ◽  
Area Under The Curve ◽  
Advanced Ovarian Cancer ◽  
Control Group ◽  
Central Research ◽  
Circulating Free Dna ◽  
Free Dna ◽  
New Biomarkers

5566 Background: Circulating free DNA (cfDNA) and circulating tumor cells (CTC) are new biomarkers for malignant tumors. Its role on ovarian epithelial cancer (OEC) is not yet well stablished. We analyze its role on advanced OEC compared with CA125 and HE4. Methods: Multicentric prospective observational study from November 2013 until February 2017, with OEC patients group (OECG), benign ovarian tumors group (BENIGNG) and health subjects control group (HEALTHG). CTCs were analysed by the CellSearch method and cfDNA by ALU-sequences-based quantitative PCR using two primers (115 and 247 bp); cfDNA integrity was calculated by ALU247/ALU115 ratio. Samples were obtained before treatment (M0), after primary peritoneal surgery (M1), after one cycle of chemotherapy (M2), before (M3) and after interval surgery (M4). This study was approved on May 2013 by the corresponding Central Research Independent Ethics Committee. Results: We analyized 102 subjects from all 3 groups (81 OECG, 14 BENIGNG y 7 HEALTHG); 68% were high grade serous subtype; most frequent staging was IIIC (58%). Within the follow-up (FU) period (average 14 months: min 0, max. 35) 36% relapses and 23% deaths were reported. CTCs were positive on 23% of OECG. In HEALTHG no positive were seen and only 1/14 in the BENIGNG group. Monitoring of cfDNA at the treatment points shows significant differences between M0 and M4 (p = 0.02). No differences were seen in the other determinations. cfDNA-ALU115 was 1.40178 ng / mcL (95% CI 1.18066-1.62290) in the OECG, 0.66383 (95% CI 0.44832-0.87935) in BENIGNG and 0.59923 in HEALTHG ( 95% CI, 0.14449-1.05397). The difference was significant between OECG and BENIGNG (P = 0.017) and near the significance between OECG and HEALTHG (p = 0.69). cfDNA integrity in OECG and HEALTHG was significantly different (P = .012). The area under the curve of Ca125, HE4, CTC, cfDNA and CFDNA integrity was 0.490, 0.526, 0.621, 0.587 and 0.450 respectively. New generation sequencing of circulating TP53 is ongoing. Conclusions: CTC and cfDNA are new biomarkers that might have an important role in the diagnosis and monitoring of OEC.

Sign in / Sign up

Export Citation Format

Share Document